RJA
ITCI

Raymond James & Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Raymond James & Associates’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$11.6M Buy
158,852
+4,325
+3% +$325K 0.01% 1135
2024
Q2 		$10.6M Sell
154,527
-1,519
-1% -$105K 0.01% 1131
2024
Q1 		$10.8M Buy
156,046
+17,191
+12% +$1.18M 0.01% 1109
2023
Q4 		$9.94M Sell
138,855
-10,590
-7% -$609K 0.01% 1113
2023
Q3 		$7.78M Buy
149,445
+5,716
+4% +$333K 0.01% 1196
2023
Q2 		$9.1M Buy
143,729
+633
+0.4% +$39.4K 0.01% 1111
2023
Q1 		$7.75M Sell
143,096
-1,802
-1% -$87.1K 0.01% 1188
2022
Q4 		$7.67M Sell
144,898
-19,234
-12% -$964K 0.01% 1157
2022
Q3 		$7.64M Buy
164,132
+14,532
+10% +$759K 0.01% 1114
2022
Q2 		$8.54M Buy
149,600
+624
+0.4% +$35.4K 0.01% 1061
2022
Q1 		$9.12M Buy
148,976
+9,233
+7% +$479K 0.01% 1122
2021
Q4 		$7.31M Buy
139,743
+5,761
+4% +$242K 0.01% 1289
2021
Q3 		$5M Buy
133,982
+20,434
+18% +$710K ﹤0.01% 1496
2021
Q2 		$4.63M Buy
113,548
+30,319
+36% +$1.12M ﹤0.01% 1540
2021
Q1 		$2.82M Buy
83,229
+880
+1% +$30.5K ﹤0.01% 1791
2020
Q4 		$2.62M Sell
82,349
-73,165
-47% -$1.92M ﹤0.01% 1734
2020
Q3 		$3.99M Sell
155,514
-9,548
-6% -$218K 0.01% 1356
2020
Q2 		$4.24M Buy
165,062
+32,209
+24% +$652K 0.01% 1291
2020
Q1 		$2.04M Sell
132,853
-2,347
-2% -$51K ﹤0.01% 1557
2019
Q4 		$4.64M Buy
135,200
+44,655
+49% +$536K 0.01% 1304
2019
Q3 		$676K Buy
90,545
+6,095
+7% +$58.4K ﹤0.01% 2448
2019
Q2 		$1.1M Buy
84,450
+15,800
+23% +$203K ﹤0.01% 2160
2019
Q1 		$836K Buy
68,650
+35,476
+107% +$453K ﹤0.01% 2313
2018
Q4 		$378K Sell
33,174
-37,626
-53% -$607K ﹤0.01% 2731
2018
Q3 		$1.54M Buy
70,800
+6,650
+10% +$139K ﹤0.01% 1971
2018
Q2 		$1.13M Buy
64,150
+15,918
+33% +$323K ﹤0.01% 2112
2018
Q1 		$1.01M Buy
48,232
+31,882
+195% +$621K ﹤0.01% 2116
2017
Q4 		$237K Buy
+16,350
New +$252K ﹤0.01% 2965

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's ITCI Position: Q3 2024 in Review

Raymond James & Associates increased its Intra-Cellular Therapies Inc. (ITCI) stake by 2.8% in Q3 2024, buying an estimated $325K and bringing the position to 158,852 shares worth $11.6M. The position accounts for 0.01% of the portfolio, ranked #1135.

Raymond James & Associates first reported a position in ITCI in Q4 2017 and has held it in 28 quarters since. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Raymond James & Associates held 158,852 shares of Intra-Cellular Therapies Inc. worth $11.6M as of Q3 2024.
  • Raymond James & Associates bought 4,325 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $325K.
  • Intra-Cellular Therapies Inc. made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1135 holding.
  • Raymond James & Associates first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and has held it in 28 quarters since.
  • 354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.